08:34 AM EDT, 03/13/2026 (MT Newswires) -- ImmunityBio ( IBRX ) said Friday it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.

The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio ( IBRX ) added.

Ten cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio ( IBRX ) said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.

ImmunityBio ( IBRX ) also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.

ImmunityBio ( IBRX ) shares were up more than 3% pre-bell Friday.